XXXX in the immediate treatment of outpatients with @entity74 without @entity146 comorbidity: randomized, double-blind, placebo-controlled study.

@entity1 @entity1910 @entity146 @entity74 @entity24265 @entity2812
OBJECTIVE: @entity74 ( @entity74 ) are highly prevalent in population. However, the effect of @entity2812 on outpatients with @entity24265 without @entity146 comorbidity has not been studied in a double-blind placebo-controlled design. METHOD: Eighty @entity1 (all @entity1 ) were washed out from all medications. Each @entity1 was randomized either to receive @entity2812 (40 @entity1 ) for 12 weeks or matched on placebo (40 @entity1 ) in a double-blind manner. Eligible @entity1 , in addition to meeting the criteria for @entity24265 from Diagnostic and Statistical Manual of @entity146 , 4th Edition, Text Revision, were required to be between 18 and 65 years. Response was defined as a 50% reduction in the Cambridge Depersonalization Scale. Response effects with @entity2812 and placebo were compared by using analysis of variance and      tests. Six @entity1 did not return for at least 1 subsequent assessment, and 74 @entity1 dropped out (36 taking @entity2812 and 38 taking placebo) in the valuables study group. RESULTS: Of the 36 @entity2812 -treated @entity1 , 26 responded by 12 weeks versus 6 of the 38 placebo-treated @entity1 (P < 0.001). The most common and problematic adverse effect in the @entity2812 group was @entity1910 . CONCLUSIONS: The authors believe this to be the first double-blind placebo-controlled randomization study to test the efficacy of @entity2812 in the management of outpatients with @entity74 . These need to be replicated in a larger study group.
